Patents Assigned to LUNG THERAPEUTICS, LLC
  • BIOMARKERS FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE
    Publication number: 20250076312
    Abstract: The present disclosure provides biomarkers associated with caveolin-1 peptide therapy in subjects with interstitial lung disease. In particular, the present disclosure describes biomarkers such as MYDGF, soluble RAGE, pSMAD2/3, and PDGFR? associated with caveolin-1 peptide therapy in subjects with idiopathic pulmonary fibrosis. These biomarkers could be used to determine efficacy, monitoring, and optimal dosing of caveolin-1 peptide therapy in subjects with interstitial lung disease.
    Type: Application
    Filed: February 25, 2022
    Publication date: March 6, 2025
    Applicant: Lung Therapeutics, LLC
    Inventors: BreAnne MACKENZIE, Cory HOGABOAM
  • DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20240269225
    Abstract: Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.
    Type: Application
    Filed: February 6, 2024
    Publication date: August 15, 2024
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, LUNG THERAPEUTICS, LLC
    Inventors: Robert O. WILLIAMS, III, Alan B. WATTS, Yajie ZHANG, Sawittree SAHAKIJPIJARN, Dale CHRISTENSEN, John J. KOLENG